Optimizing screening and management of cardiovascular health in prostate cancer
Miran Kenk, Jean‐Claude Grégoire, Marc‐André Côté, Kim A. Connelly, Margot K. Davis, George K. Dresser, Nina Ghosh, Shaun G. Goodman, Christopher Johnson, Neil Fleshner
Abstract
In clinical practice, cancer management does not consistently encompass screening and identification of cardiovascular (CV) risk. The use of androgen deprivation therapy (ADT) in prostate cancer has been associated with increased CV risk and development of metabolic syndrome, necessitating identification of patients at risk in this population (e.g., those with pre-existing CV disease). A multidisciplinary team of Canadian physicians was assembled to develop a series of recommendations intended to identify patients who may benefit from optimal management of their CV disease and/or modification of cardiac risk factors. A key goal was the development of a simple screening tool for identification of patients with pre-existing CV disease. This simple and inclusive set of recommendations are intended for use within urology clinics to facilitate holistic approaches and simplify the management of patients.